An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

被引：0
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Kim, Dong-Wook [2 ]
Kantarjian, Hagop M. [3 ]
Brummendorf, Tim H. [4 ,5 ,11 ]
Dyagil, Irina [6 ]
Griskevicius, Laimonas [7 ]
Malhotra, Hemant [8 ]
Goh, Yeow-Tee [9 ]
Wang, Junyuan [10 ]
Gogat, Karin [10 ]
Cortes, Jorge [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Seoul St Marys Hosp, Seoul, South Korea
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[5] Univ Klinikum Aachen, Hamburg, Germany
[6] Ukraine Acad Med Sci, Res Ctr Radiat Med, Kiev, Ukraine
[7] Vilnius Univ Hosp, Santarigkio Klin, Vilnius, Lithuania
[8] SMS Med Coll & Hosp, Birla Canc Ctr, Jaipur, Rajasthan, India
[9] Singapore Gen Hosp, Singapore 0316, Singapore
[10] Pfizer Inc, Cambridge, MA USA
[11] Univ Klinikum Aachen, Aachen, Germany
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib (vol 118, pg 4567, 2011)
    Cortes, J. E.
    Kantarjian, H. M.
    Bruemmendorf, T. H.
    BLOOD, 2013, 122 (14) : 2524 - 2524
  • [22] Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial
    Deininger, Michael W.
    Kota, Vamsi
    Lipton, Jeff H.
    Milojkovic, Dragana
    Garcia Gutierrez, Valentin
    Leip, Eric
    Nick, Sonja
    Hochhaus, Andreas
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Brummendorf, Tim H.
    BLOOD, 2018, 132
  • [23] Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia-BELA Trial
    Gambacorti-Passerini, Carlo
    Bruemmendorf, Tim H.
    Kim, Dong-Wook
    Dyagil, Irina
    Kantarjian, Hagop M.
    Pavlov, Dmitri
    Gogat, Karin
    Duvillie, Ladan
    Shapiro, Mark
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [24] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Charles Chuah
    Liang Piu Koh
    Tontanai Numbenjapon
    Dae Young Zang
    Kiat Hoe Ong
    Young Rok Do
    Masayuki Ohkura
    Chiho Ono
    Andrea Viqueira
    Jorge E. Cortes
    Tim H. Brümmendorf
    International Journal of Hematology, 2021, 114 : 65 - 78
  • [26] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Chuah, Charles
    Koh, Liang Piu
    Numbenjapon, Tontanai
    Zang, Dae Young
    Ong, Kiat Hoe
    Do, Young Rok
    Ohkura, Masayuki
    Ono, Chiho
    Viqueira, Andrea
    Cortes, Jorge E.
    Brummendorf, Tim H.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (01) : 65 - 78
  • [27] Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
    Wang, Jianxiang
    Shen, Zhi-Xiang
    Saglio, Giuseppe
    Jin, Jie
    Huang, He
    Hu, Yu
    Du, Xin
    Li, Jianyong
    Meng, Fanyi
    Zhu, Huanling
    Hu, Jianda
    Wang, Jianmin
    Hou, Ming
    Hertle, Sabine
    Menssen, Hans D.
    Ortmann, Christine-Elke
    Tribouley, Catherine
    Yuan, Ye
    Baccarani, Michele
    Huang, Xiaojun
    BLOOD, 2015, 125 (18) : 2771 - 2778
  • [28] Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure
    Whiteley, Jennifer
    Reisman, Arlene
    Shapiro, Mark
    Cortes, Jorge E.
    Cella, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (08) : 1325 - 1334
  • [29] A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia (CML)
    Takahashi, Naoto
    Ishizawa, Kenichi
    Nakaseko, Chiaki
    Kobayashi, Yukio
    Ohashi, Kazuteru
    Nakagawa, Yasunori
    Yamamoto, Kazuhito
    Miyamura, Koichi
    Taniwaki, Masafumi
    Okada, Masaya
    Kawaguchi, Tatsuya
    Shibata, Atsushi
    Fujii, Yosuke
    Ono, Chiho
    Ohnishi, Kazunori
    BLOOD, 2013, 122 (21)
  • [30] Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia - BELA Trial: 24-Month Follow-up
    Cortes, Jorge E.
    Maru, Anish
    Antonio De Souza, Carmino Antonio
    Guilhot, Francois
    Duvillie, Ladan
    Powell, Christine
    Countouriotis, Athena
    Gambacorti-Passerini, Carlo
    BLOOD, 2011, 118 (21) : 210 - 211
12345